CY1109880T1 - ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR - Google Patents

ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR

Info

Publication number
CY1109880T1
CY1109880T1 CY20101100234T CY101100234T CY1109880T1 CY 1109880 T1 CY1109880 T1 CY 1109880T1 CY 20101100234 T CY20101100234 T CY 20101100234T CY 101100234 T CY101100234 T CY 101100234T CY 1109880 T1 CY1109880 T1 CY 1109880T1
Authority
CY
Cyprus
Prior art keywords
casr
component
compound
receptor antagonist
calcium receptor
Prior art date
Application number
CY20101100234T
Other languages
English (en)
Inventor
Yuko Shinagawa
Teruhiko Inoue
Toshihiro Kiguchi
Taku Ikenogami
Naoki Ogawa
Kenji Fukuda
Takashi Nakagawa
Masanori Shindo
Yuki Soejima
Original Assignee
Japan Tobacco, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco, Inc. filed Critical Japan Tobacco, Inc.
Publication of CY1109880T1 publication Critical patent/CY1109880T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Abstract

Προσφέρονται (προμηθεύονται) ένωσις παριστωμένη υπό του επόμενου (1), φαρμακευτικώς αποδεκτόν άλας αυτής ή οπτικώς ενεργός μορφή αυτής: ένθα έκαστον σύμβολον είναι ως καθορίζεται εις την περιγραφήν. Ένωσις έχουσα ανταγωνιστικής δράσιν υποδοχέως εκτιμήσεως-ασβεστίου, φαρμακευτική σύνθεσις περιλαμβάνουσα την ένωσιν, ιδιαιτέρως ανταγωνιστήν υποδοχέως ασβεστίου και θεραπευτικών φάρμακον δι’ οστεοπόρωσιν.
CY20101100234T 2003-04-23 2010-03-10 ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR CY1109880T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003119131 2003-04-23
EP04729243A EP1619180B1 (en) 2003-04-23 2004-04-23 CaSR ANTAGONIST

Publications (1)

Publication Number Publication Date
CY1109880T1 true CY1109880T1 (el) 2014-09-10

Family

ID=33308093

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100234T CY1109880T1 (el) 2003-04-23 2010-03-10 ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR

Country Status (31)

Country Link
US (4) US7304174B2 (el)
EP (3) EP2308828A3 (el)
JP (1) JP3751312B2 (el)
KR (1) KR100696927B1 (el)
CN (2) CN100577633C (el)
AR (1) AR044075A1 (el)
AT (1) ATE452121T1 (el)
AU (1) AU2004232604C1 (el)
BR (1) BRPI0407097A (el)
CA (1) CA2513738C (el)
CL (1) CL2004000868A1 (el)
CO (1) CO5640091A2 (el)
CY (1) CY1109880T1 (el)
DE (1) DE602004024668D1 (el)
DK (1) DK1619180T3 (el)
ES (1) ES2337576T3 (el)
HK (1) HK1083096A1 (el)
HR (1) HRP20100042T1 (el)
IL (1) IL169575A (el)
MX (1) MXPA05007609A (el)
MY (1) MY138734A (el)
NO (1) NO20054868L (el)
NZ (1) NZ541188A (el)
PE (1) PE20050460A1 (el)
PL (1) PL1619180T3 (el)
PT (1) PT1619180E (el)
RU (1) RU2315036C2 (el)
SI (1) SI1619180T1 (el)
TW (1) TWI329628B (el)
WO (1) WO2004094362A1 (el)
ZA (1) ZA200505587B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
CA2527203C (en) * 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist
WO2005077886A1 (en) * 2004-02-06 2005-08-25 Smithkline Beecham Corporation Calcilytic compounds
US8779004B2 (en) * 2006-04-20 2014-07-15 Amgen, Inc. Stable emulsion formulations
EP2139462B1 (en) 2007-03-30 2014-01-22 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
CN102056897B (zh) * 2008-06-05 2014-05-07 旭化成制药株式会社 磺酰胺化合物及其用途
BRPI0923654A2 (pt) * 2008-12-24 2018-10-16 Daiichi Sankyo Company, Limited composto, uso de um composto, e , composição farmacêutica.
JP5628687B2 (ja) * 2008-12-24 2014-11-19 第一三共株式会社 インダニル化合物
WO2010103429A1 (en) * 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
WO2010104882A1 (en) 2009-03-10 2010-09-16 Amgen Inc. Methods of modulating sperm motility
WO2010110352A1 (ja) * 2009-03-26 2010-09-30 日本たばこ産業株式会社 カルボン酸化合物の製造方法
WO2010113860A1 (ja) * 2009-03-31 2010-10-07 第一三共株式会社 ビフェニル－環状アミン化合物
US8785494B2 (en) 2009-05-27 2014-07-22 Leo-Pharma A/S Calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
EP2643291A2 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Calcium-sensing receptor-active compounds
RU2013128950A (ru) * 2010-11-26 2015-01-10 Лео Фарма А/С Замещенные циклопентилазины в качестве casr-активных соединений
WO2012069421A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
CN103270018A (zh) 2010-11-26 2013-08-28 利奥制药有限公司 钙敏感受体激活化合物
GB201113538D0 (en) * 2011-08-04 2011-09-21 Karobio Ab Novel estrogen receptor ligands
IN2015MN00421A (el) * 2012-08-27 2015-09-04 Lupin Ltd
WO2017215591A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Use of lithium benzoate for treating central nervous system disorders
KR20220110789A (ko) * 2019-12-09 2022-08-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 칼슘 감지 수용체 효능제 화합물 및 이의 응용
MX2023001438A (es) 2020-08-04 2023-06-15 Calcilytix Therapeutics Inc Formulaciones de compuestos calciliticos de trifenilo.
US20220087961A1 (en) * 2020-09-18 2022-03-24 Calcilytix Therapeutics, Inc. Treatment methods of triphenyl calcilytic compounds

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE633760A (el) * 1963-06-18
DD207203A1 (de) * 1982-06-21 1984-02-22 Peter Meisel Verfahren zur herstellung von epoxypropylethern
DE3743265A1 (de) * 1987-12-19 1989-06-29 Boehringer Ingelheim Kg Neue ammoniumverbindungen, ihre herstellung und verwendung
US5276008A (en) * 1990-08-09 1994-01-04 Bayer Aktiengesellschaft Substituted 4,5-diamino-1,2,4-triazol-3-(thi)ones
JP2001501584A (ja) 1996-04-09 2001-02-06 エヌピーエス・ファーマシウティカルズ・インコーポレイテッド カルシリチック化合物
US6818660B2 (en) 1996-04-09 2004-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
ATE215369T1 (de) * 1996-09-05 2002-04-15 Lilly Co Eli Carbazolanaloge als selektive beta3-adrenergische agonisten
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos
AR014975A1 (es) 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento
MY121054A (en) 1998-04-08 2005-12-30 Smithkline Beecham Corp Calcilytic compounds as calcium receptor antagonists.
US20020052509A1 (en) 1998-04-08 2002-05-02 Smithkline Beecham Corporation Calcilytic compounds and method of use
US6334338B1 (en) 1998-07-02 2002-01-01 Lucent Technologies Inc. Sol gel process of making a fiber preform with removal of oxide particles
JP2002522499A (ja) 1998-08-12 2002-07-23 スミスクライン・ビーチャム・コーポレイション カルシウム分解化合物
CA2340341A1 (en) 1998-08-12 2000-02-24 Smithkline Beecham Corporation Calcilytic compounds
ID28276A (id) * 1998-10-23 2001-05-10 Hoffmann La Roche Heterolingkar nitrogen bisiklik
PE20001456A1 (es) 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
CA2382119A1 (en) * 1999-08-27 2001-03-08 The Procter & Gamble Company Fast-acting formulation components, compositions and laundry methods employing same
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
MY159417A (en) 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
BR0112600A (pt) 2000-07-21 2003-06-24 Smithkline Beecham Corp Compostos calcilìticos
WO2002014259A1 (fr) * 2000-08-11 2002-02-21 Japan Tobacco Inc. Antagonistes du recepteur de calcium
KR20040007407A (ko) 2000-10-25 2004-01-24 스미스클라인 비참 코포레이션 칼실리틱 화합물
JP2004514659A (ja) 2000-10-25 2004-05-20 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
US6864267B2 (en) 2001-07-16 2005-03-08 Smithkline Beecham Corporation Calcilytic compounds
CA2527203C (en) * 2003-05-28 2010-08-17 Japan Tobacco Inc. Casr antagonist

Also Published As

Publication number Publication date
PL1619180T3 (pl) 2010-05-31
AU2004232604C1 (en) 2008-06-05
US20080255042A1 (en) 2008-10-16
CA2513738C (en) 2010-04-06
PT1619180E (pt) 2009-12-29
EP1619180B1 (en) 2009-12-16
DE602004024668D1 (de) 2010-01-28
NZ541188A (en) 2008-01-31
RU2315036C2 (ru) 2008-01-20
BRPI0407097A (pt) 2006-01-24
ZA200505587B (en) 2006-09-27
CL2004000868A1 (es) 2005-01-21
RU2005123985A (ru) 2006-01-27
AU2004232604B8 (en) 2004-11-04
EP2189439A3 (en) 2011-05-04
NO20054868L (no) 2005-12-20
EP1619180A1 (en) 2006-01-25
AR044075A1 (es) 2005-08-24
US20120301552A1 (en) 2012-11-29
IL169575A (en) 2011-07-31
KR20050094047A (ko) 2005-09-26
SI1619180T1 (sl) 2010-04-30
HK1083096A1 (en) 2006-06-23
MY138734A (en) 2009-07-31
HRP20100042T1 (hr) 2010-02-28
EP2308828A3 (en) 2013-05-22
JP3751312B2 (ja) 2006-03-01
AU2004232604B2 (en) 2007-09-13
EP1619180A4 (en) 2006-05-24
IL169575A0 (en) 2007-07-04
PE20050460A1 (es) 2005-07-08
CO5640091A2 (es) 2006-05-31
US7304174B2 (en) 2007-12-04
AU2004232604A8 (en) 2004-11-04
EP2308828A2 (en) 2011-04-13
US20050032796A1 (en) 2005-02-10
CN101723921A (zh) 2010-06-09
NO20054868D0 (no) 2005-10-21
US20090326058A1 (en) 2009-12-31
DK1619180T3 (da) 2010-03-29
KR100696927B1 (ko) 2007-03-20
CN100577633C (zh) 2010-01-06
EP2189439A2 (en) 2010-05-26
TWI329628B (en) 2010-09-01
JPWO2004094362A1 (ja) 2006-07-13
ATE452121T1 (de) 2010-01-15
CN1741984A (zh) 2006-03-01
TW200505823A (en) 2005-02-16
CA2513738A1 (en) 2004-11-04
ES2337576T3 (es) 2010-04-27
WO2004094362A1 (ja) 2004-11-04
MXPA05007609A (es) 2005-09-30
AU2004232604A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
CY1116693T1 (el) Συνδυασμος αζελαστινης και κυκλεσονιδης
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
DE602004024375D1 (de) Carboxamidderivate
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
IS7076A (is) Bólusetning með einföldum skammti af Mycoplasma hyopneumoniae, og notkun efnisins í lækningaskyni
NO20065904L (no) Terapeutiske forbindelser
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
DK1814848T3 (da) 2,3,4-substitueret-cyclopentanoner som terapeutiske midler
SE0302192D0 (sv) Novel compounds
ATE354362T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
DE60302157D1 (de) Opioidrezeptorantagonisten
UY27424A1 (es) Agentes antidiabéticos
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof